Valneva SE, a leading European biotech company specializing in innovative vaccines, reports earnings for the first half of 2017. Thomas Lingelbach, President & CEO of Valneva, comments on the results ...

Once neck and neck with Valneva to get the first chikungunya vaccine to market, it now looks like Merck & Co. has admitted defeat as its French rival reaches the finish line. Merck’s contender was ...

European countries' decisions to backtrack on their large orders of Valneva’s COVID-19 vaccine appeared to have sunk the company’s hopes of developing a successor shot. But the French biotech is now ...

Valneva SE (NASDAQ:VALN), on Monday, sold the FDA Priority Review Voucher (PRV) for $103 million (€95 million). The company was awarded a tropical disease PRV in November 2023 following the FDA ...

As safety flags hang over Valneva’s chikungunya vaccine in the U.S. and beyond, French authorities are clamping down on the shot’s use in older adults. France’s public health agency, the Haute ...

Monday - Friday, 08:00 - 11:00 CET | 14:00 - 17:00 HK/SG Thomas Lingelbach discusses Valneva's European Commission approval to supply 60 million doses of its Covid-19 vaccine candidate over two years, ...

After striking out in an attempt to create a niche for its COVID-19 vaccine, Valneva is taking its swings at what it does best—developing, manufacturing and commercializing vaccines for a variety of ...

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially ...

Valneva SE (NASDAQ:VALN) on Thursday announced six-month antibody persistence and safety data for its Phase 2 trial evaluating the safety and immunogenicity of two different dose levels of its ...

LONDON, Aug 8 (Reuters) - With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva (VLS.PA), opens new tab is betting big on a vaccine as it looks beyond disappointing ...